Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma
jRCT1080221832Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, double-blind trial of denosumab in multiple myeloma (MM) and Malignant bone disease (MBD) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Time to first on-study skeletal-related event (SRE). Started Jun 2012; status: completed.
02
Drugs
denosumab
03
Conditions
multiple myeloma (MM)Malignant bone disease (MBD)
Beyond the preview
Go deeper on jRCT1080221832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221832.